The incidence and time course of adverse effects of ticlopidine after percutaneous coronary intervention

Japanese Journal of Interventional Cardiology

Volumn 20, Issue 3, 2005, Pages 203-210

  Endo, Goro ^a   Kozuma, Ken ^a   Watanabe, Suguru ^a   Motoyoshi, Kentaro ^a   Ishikawa, Shuichi ^a   Suzuki, Nobuaki ^a   Kyouno, Hiroyuki ^a   Kawamura, Yutaka ^a   Terakura, Moriyuki ^a   Suzuki, Masatoshi ^a   Yokoyama, Naoyuki ^a   Yamamoto, Yoshito ^a   Takeshita, Satoshi ^a   Isshiki, Takaaki ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse effects; Antiplatelet therapy; PCI

Indexed keywords

ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; CORONARY STENT; DISEASE DURATION; DOSE TIME EFFECT RELATION; DRUG ELUTING STENT; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FEMALE; HUMAN; IMPLANTATION; INCIDENCE; LIVER DYSFUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METHODOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RASH; SYMPTOMATOLOGY; THROMBOSIS; VALIDATION PROCESS;

EID: 21744452623     PISSN: 09148922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Braunwald E, et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Col Cardiol 40: 1366-1374, 2002.
2. Shankar K, et al: Streptozotocin-induced diabetic mice are resistant to lethal effects of thioacetamide hepatotoxicity. Toxicol Appl Pharmacol 188: 122-134, 2003.
3. Shankar K, et al: Type 1 diabetic mice are protected from acetaminophen hepatotoxicity. Toxicol Sci 73: 220-234, 2003.
4. Ha-Duong NT, et al: Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P 4502 C 19. Biochemistry 40: 12112-1212, 2001.
5. Love BB, et al: Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 19: 89-98, 1998.
6. Hass WK, et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321: 501-507, 1989.
7. Gent M, et al: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1 (8649): 1215-1220, 1989.
8. Janzon L, et al: Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 227: 301-308, 1990.
9. Balsano F, et al: Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 82: 17-26, 1990.
10. Leon MB, et al: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339: 1665-1671, 1998.
11. Bertrand ME, et al: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 98: 1597-1603, 1998.
12. Szto GY, et al: Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 83: 138-139, A10, 1999.
13. Ono K, et al: Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 37: 239-242, 1991.
14. Farver DK, et al: Delayed neutropenia with ticlopidine. Ann Pharmacother 28: 1344-1346, 1994.
15. Yosipovitch G, et al: Adverse cutaneous reactions to ticlopidine in patients with coronary stents. J Am Acad Dermatol 41: 473-476, 1999.
16. Steinhubl SR, et al: Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of PlateletIIb/IIIa Inhibitor for Stenting. JAMA 281: 806-810, 1999.
17. Symeonidis A, et al: Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol 71: 24-32, 2002.
18. Bhatt DL, et al: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39: 9-14, 2002.